Literature DB >> 25953524

Decreased orexin (hypocretin) immunoreactivity in the hypothalamus and pontine nuclei in sudden infant death syndrome.

Nicholas J Hunt1, Karen A Waters, Michael L Rodriguez, Rita Machaalani.   

Abstract

Infants at risk of sudden infant death syndrome (SIDS) have been shown to have dysfunctional sleep and poor arousal thresholds. In animal studies, both these attributes have been linked to impaired signalling of the neuropeptide orexin. This study examined the immunoreactivity of orexin (OxA and OxB) in the tuberal hypothalamus (n = 27) and the pons (n = 15) of infants (1-10 months) who died from SIDS compared to age-matched non-SIDS infants. The percentage of orexin immunoreactive neurons and the total number of neurons were quantified in the dorsomedial, perifornical and lateral hypothalamus at three levels of the tuberal hypothalamus. In the pons, the area of orexin immunoreactive fibres were quantified in the locus coeruleus (LC), dorsal raphe (DR), laterodorsal tegmental (LDT), medial parabrachial, dorsal tegmental (DTg) and pontine nuclei (Pn) using automated methods. OxA and OxB were co-expressed in all hypothalamic and pontine nuclei examined. In SIDS infants, orexin immunoreactivity was decreased by up to 21 % within each of the three levels of the hypothalamus compared to non-SIDS (p ≤ 0.050). In the pons, a 40-50 % decrease in OxA occurred in the all pontine nuclei, while a similar decrease in OxB immunoreactivity was observed in the LC, LDT, DTg and Pn (p ≤ 0.025). No correlations were found between the decreased orexin immunoreactivity and previously identified risk factors for SIDS, including prone sleeping position and cigarette smoke exposure. This finding of reduced orexin immunoreactivity in SIDS infants may be associated with sleep dysfunction and impaired arousal.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25953524     DOI: 10.1007/s00401-015-1437-9

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  7 in total

1.  The Unfolded Protein Response in the Human Infant Brain and Dysregulation Seen in Sudden Infant Death Syndrome (SIDS).

Authors:  Shannon Thomson; Karen A Waters; Rita Machaalani
Journal:  Mol Neurobiol       Date:  2021-01-08       Impact factor: 5.590

2.  Hypoxia and hypercapnia inhibit hypothalamic orexin neurons in rats.

Authors:  Olga Dergacheva; Akihiro Yamanaka; Alan R Schwartz; Vsevolod Y Polotsky; David Mendelowitz
Journal:  J Neurophysiol       Date:  2016-08-24       Impact factor: 2.714

3.  Orexin contributes to eupnea within a critical period of postnatal development.

Authors:  Richard L Spinieli; Ruwaida Ben Musa; Jane Kielhofner; Jennifer Cornelius-Green; Kevin J Cummings
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2021-08-18       Impact factor: 3.210

4.  Assessment of Safe Sleep: Validation of the Parent Newborn Sleep Safety Survey.

Authors:  Leanne Whiteside-Mansell; Rosemary Nabaweesi; Alison Rose Caballero; Samantha Hope Mullins; Beverly Kaye Miller; Mary Elizabeth Aitken
Journal:  J Pediatr Nurs       Date:  2017-03-08       Impact factor: 2.145

5.  Prenatal intermittent hypoxia sensitizes the laryngeal chemoreflex, blocks serotoninergic shortening of the reflex, and reduces 5-HT3 receptor binding in the NTS in anesthetized rat pups.

Authors:  William T Donnelly; Robin L Haynes; Kathryn G Commons; Drexel J Erickson; Chris M Panzini; Luxi Xia; Q Joyce Han; J C Leiter
Journal:  Exp Neurol       Date:  2019-12-27       Impact factor: 5.330

6.  Cerebrospinal Fluid Histamine Levels in Healthy Children and Potential Implication for SIDS: Observational Study in a French Tertiary Care Hospital.

Authors:  Sabine Plancoulaine; Aurore Guyon; Clara-Odilia Inocente; Philippine Germe; Min Zhang; Philippe Robert; Jian-Sheng Lin; Patricia Franco
Journal:  Front Pediatr       Date:  2022-04-05       Impact factor: 3.418

7.  A "Wear and Tear" Hypothesis to Explain Sudden Infant Death Syndrome.

Authors:  Eran Elhaik
Journal:  Front Neurol       Date:  2016-10-28       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.